X37
Kiersten Stead is a highly experienced professional in the biotechnology and life sciences sectors, currently serving as a Board Member for multiple companies, including Nilo Therapeutics, Radionetics Oncology, Latus Bio, Totus Medicines, Mycoworks, Stemson Therapeutics, and Elo Life Systems. Since May 2018, Kiersten has also held the position of Managing Partner at DCVC Bio. Additional roles include serving on the Scientific Advisory Board of Keystone Symposia on Molecular & Cellular Biology since January 2014, and Board Member for Creyon Bio from June 2021 to September 2024. Kiersten's academic credentials include a Ph.D. in Molecular Biology and Genetics from the University of Alberta, an MBA with a Finance specialization from the same institution, and a B.Sc. in Cellular, Molecular and Microbial Biology from the University of Calgary.
This person is not in the org chart
This person is not in any teams
X37
2 followers
X-37 has closed a $14.5 million Series A financing, led by DCVC Bio and joined by Alpha Intelligence Capital and Hemi Ventures. X-37 was cofounded by AtomWise and an experienced team of pharmaceutical developers from Velocity Pharmaceutical Development. With AtomWise’s top #AI platform, we have already generated promising hits against ZAP-70 for autoimmune diseases, PIM3 and SHP2 for #cancer, and Factor XIIa #anticoagulation.